Who are we?
Amyllab, led by Dr. Gažová, has been dedicated to studying the phenomenon of amyloid aggregation for the past two decades. Specific amyloid self-assemblies are associated with the pathogenesis of many diseases, including Alzheimer's and Parkinson's diseases, as well as type II diabetes. Our research group has three long-term goals related to amyloid formation:
• To elucidate the mechanism of protein amyloid aggregation.
• To examine the role of low-molecular substances and/or nanoparticles in the destruction of amyloids or the inhibition of the aggregation process.
• To establish methods for the early detection of Alzheimer's disease.
Our work focuses on the formation of specific amyloid aggregates, which are implicated in the pathogenesis of many diseases such as Alzheimer's, Parkinson's, and type II diabetes. We are dedicated to studying the aggregation of poly/peptides (including insulin, lysozyme, and amyloid β peptides) in the presence of small molecules and nanoparticles in vitro, and their effects on cell cultures. Our ultimate aim is to identify amyloid inhibitors that could serve as potential therapeutic agents for diseases associated with amyloid aggregation. Additionally, we are focusing on detecting protein level changes in the cerebrospinal fluid of Alzheimer's patients, with the goal of finding novel options for early disease detection.